Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy.

NPJ precision oncology·2026
Same author

The promyelocytic leukemia PML protein coordinates immune evasion in triple-negative breast cancer via independent and converging mechanisms.

Cell death and differentiation·2026
Same author

Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.

The New England journal of medicine·2026
Same author

Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer.

NPJ breast cancer·2025
Same author

Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies.

Nature communications·2025
Same author

Development and validation of a gene expression-based Breast Cancer Purity Score.

NPJ precision oncology·2024

Related Experiment Video

Updated: Mar 10, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

805

HER2-positive breast cancer.

Sibylle Loibl1, Luca Gianni2

  • 1German Breast Group, c/o GB Forschungs GmbH, Neu-Isenburg, Germany.

Lancet (London, England)
|December 13, 2016
PubMed
Summary

Anti-HER2 therapies have transformed HER2-positive breast cancer treatment, improving survival and pathological complete response rates. Continued research is vital due to persistent mortality from this disease.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • HER2-positive breast cancer presents a significant clinical challenge.
  • Anti-HER2 therapies have revolutionized treatment paradigms.

Purpose of the Study:

  • To review key advancements in treating metastatic and early HER2-positive breast cancer.
  • To highlight the impact of anti-HER2 therapies on patient outcomes.

Main Methods:

  • Review of clinical data and treatment outcomes for HER2-positive breast cancer.
  • Analysis of neoadjuvant and adjuvant therapy studies.

Main Results:

  • Pertuzumab and trastuzumab demonstrated higher pathological complete response rates in neoadjuvant settings.
  • Improved event-free survival observed with combination therapy.

More Related Videos

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

13.1K

Related Experiment Videos

Last Updated: Mar 10, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

805
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

13.1K
  • Survival rates for metastatic HER2-positive breast cancer approach 5 years.

    • Conclusions:

    • Anti-HER2 treatments have significantly improved prognosis for HER2-positive breast cancer.
    • Despite progress, ongoing research into novel therapies is crucial to reduce mortality.